1. Xu W. Novel drug design and development. 1st Ed. Beijing: Science Press, 2001. 104–105
2. Ripka A S, Rich D H. Peptidomimetic design. Curr Opin Chem Biol, 1998, 2(4): 441–452
3. Williams T M, Ciccarone T M, MacTough S C, Bock R L, Conner M W, Davide J P, Hamilton K, Koblan K S, Kohl N E, Kral A M, Mosser S D, Omer C A, Pompliano D L, Rands E, Schaber M D, Shah D, Wilson F R, Gibbs J B, Graham S L, Hartman G D, Oliff A I, Smith R L. 2-Substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyl-transferase. J Med Chem, 1996, 39(7): 1345–1348
4. Kim J, Sieburth S M. Silanediol peptidomimetics. Evaluation of four diastereomeric ACE inhibitors. Bioorg Med Chem Lett, 2004, 14(11): 2853–2856
5. Carron C P, Meyer D M, Pegg J A, Engleman V M, Nickols M A, Settle S L, Westlin W F, Ruminski P G, Nickols G A. A peptidomimetic antagonist of the integrin αvβ3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res, 1998, 58(9): 1930–1935